Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.

Orwoll ES, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C, Reeder JL, Keaveny TM, Lee DC, Mullins MA, Nagamani SC, Lee B

The Journal of clinical investigation27 Jan 2014Cited by 145 (Europe PMC)

PMID24463451PMCIDPMC3904621DOI10.1172/jci71101PepBankPUB-24463451

Source link PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with osteogenesis imperfecta, lumbar spine areal BMD increased 6.1% with teriparatide versus 2.8% with placebo.
In plain wordsIn adults with osteogenesis imperfecta, teriparatide increased spine bone density more than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine areal BMD
Study
n = 79
Comparator
Placebo
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · 18 monthsAs given in this study (human).
Measurements
Lumbar spine aBMD change from baseline
6.1%
teriparatide group
Lumbar spine aBMD change from baseline
2.8%
placebo group
Source sentences
Summary
Compared with the placebo group, the teriparatide group showed increased LS aBMD (6.1% ± 1.0% vs. 2.8% ± 1.0% change from baseline; P < 0.05) and total hip aBMD (2.6% ± 1.0% vs. -2.4% ± 1.0% change; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial.
Report a problemFND-2446345101
02HumanRandomized controlled trialEfficacy outcome
In adults with osteogenesis imperfecta, vertebral volumetric BMD changed 18% with teriparatide versus -5.0% with placebo.
In plain wordsIn adults with osteogenesis imperfecta, teriparatide improved vertebral volumetric bone density compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral volumetric BMD
Study
n = 79
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · 18 monthsAs given in this study (human).
Measurements
Vertebral vBMD change
18%
teriparatide group
Vertebral vBMD change
−5%
placebo group
Source sentences
Summary
Vertebral vBMD and strength improved with teriparatide therapy (18% ± 6% and 15% ± 3% change, respectively), but declined with placebo (-5.0% ± 6% and -2.0% ± 3% change; P < 0.05 for both comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial.
Report a problemFND-2446345103
03HumanRandomized controlled trialEfficacy outcome
In adults with osteogenesis imperfecta, estimated vertebral strength changed 15% with teriparatide versus -2.0% with placebo.
In plain wordsIn adults with osteogenesis imperfecta, teriparatide improved estimated spine strength compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral strength
Study
n = 79
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · 18 monthsAs given in this study (human).
Measurements
Estimated vertebral strength change
15%
teriparatide group
Estimated vertebral strength change
−2%
placebo group
Source sentences
Summary
Vertebral vBMD and strength improved with teriparatide therapy (18% ± 6% and 15% ± 3% change, respectively), but declined with placebo (-5.0% ± 6% and -2.0% ± 3% change; P < 0.05 for both comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial.
Report a problemFND-2446345104
04HumanRandomized controlled trialEfficacy outcome
In adults with osteogenesis imperfecta, self-reported fractures did not differ between teriparatide and placebo.
In plain wordsIn adults with osteogenesis imperfecta, reported fractures did not differ between teriparatide and placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSelf-reported fractures
Study
n = 79
Comparator
Placebo
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · 18 monthsAs given in this study (human).
Source sentences
Summary
There was no difference in self-reported fractures between the 2 groups.
1 context sentence(design, population, supporting numbers)
Summary · context
79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial.
Report a problemFND-2446345110
05HumanRandomized controlled trialEfficacy outcome
In adults with osteogenesis imperfecta, serum P1NP increased 135% with teriparatide.
In plain wordsIn adults with osteogenesis imperfecta, a blood marker of bone formation increased with teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum P1NP
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · 18 monthsAs given in this study (human).
Measurements
Serum P1NP change
135%
teriparatide group
Source sentences
Summary
Serum procollagen type 1 N-terminal propeptide (P1NP) and urine collagen N-telopeptide (NTx) levels increased with teriparatide therapy (135% ± 14% and 64% ± 10% change, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial.
Report a problemFND-2446345105
06HumanRandomized controlled trialEfficacy outcome
In adults with osteogenesis imperfecta, urine NTx increased 64% with teriparatide.
In plain wordsIn adults with osteogenesis imperfecta, a urine marker of bone breakdown increased with teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUrine NTx
Study
n: not reported in source
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · 18 monthsAs given in this study (human).
Measurements
Urine NTx change
64%
teriparatide group
Source sentences
Summary
Serum procollagen type 1 N-terminal propeptide (P1NP) and urine collagen N-telopeptide (NTx) levels increased with teriparatide therapy (135% ± 14% and 64% ± 10% change, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial.
Report a problemFND-2446345106
07HumanRandomized controlled trialEfficacy outcome
In adults with osteogenesis imperfecta, hip areal BMD changed 2.6% with teriparatide versus -2.4% with placebo.
In plain wordsIn adults with osteogenesis imperfecta, teriparatide increased hip bone density compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip areal BMD
Study
n = 79
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · 18 monthsAs given in this study (human).
Measurements
Total hip aBMD change
2.6%
teriparatide group
Total hip aBMD change
−2.4%
placebo group
Source sentences
Summary
Compared with the placebo group, the teriparatide group showed increased LS aBMD (6.1% ± 1.0% vs. 2.8% ± 1.0% change from baseline; P < 0.05) and total hip aBMD (2.6% ± 1.0% vs. -2.4% ± 1.0% change; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial.
Report a problemFND-2446345102
08HumanRandomized controlled trialEfficacy outcome
Adults with type III/IV osteogenesis imperfecta showed no observed BMD benefit from teriparatide versus placebo.
In plain wordsIn adults with severe osteogenesis imperfecta, teriparatide showed no observed bone density benefit compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBMD response in type III/IV OI
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg · 18 monthsAs given in this study (human).
Source sentences
Summary
Type I OI patients exhibited robust BMD increases with teriparatide; however, there was no observed benefit for those with type III/IV OI.
1 context sentence(design, population, supporting numbers)
Summary · context
79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial.
Report a problemFND-2446345109

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

09HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
Teriparatide-induced P1NP elevation was less pronounced in adults with type III/IV than type I osteogenesis imperfecta.
In plain wordsTeriparatide raised a bone formation marker less in severe osteogenesis imperfecta than in its milder form.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseP1NP response by OI severity
Study
n: not reported in source
Comparator
Type I OI receiving teriparatide
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Teriparatide-induced elevation of P1NP levels was less pronounced in severe forms of OI (type III/IV) compared with the milder form (type I).
1 context sentence(design, population, supporting numbers)
Summary · context
79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2446345107
10HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In adults with osteogenesis imperfecta given teriparatide, type I patients showed robust BMD increases while type III/IV patients showed no observed benefit.
In plain wordsIn adults with osteogenesis imperfecta given teriparatide, bone density rose in type I but showed no observed benefit in types III/IV.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBMD response by OI type
Study
n: not reported in source
Comparator
Type III/IV OI receiving teriparatide
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Type I OI patients exhibited robust BMD increases with teriparatide; however, there was no observed benefit for those with type III/IV OI.
1 context sentence(design, population, supporting numbers)
Summary · context
79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2446345108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT00131469

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

Oregon Health and Science Universityn = 79Jun 2005 to Jan 2011

Osteogenesis Imperfecta

Trial page ClinicalTrials.govUpdated 24 Apr 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.